MiMedx Group Launches Newest Tissue Product

During an event that’s used to discussions and product launches in the large-joint realm, the MiMedx Group Inc. is pursuing a “softer” approach.

During this year’s annual meeting of the American Academy of Orthopaedic Surgeons in San Francisco, Calif., the company—a developer of regenerative biomaterials and bioimplants processed from human amniotic membrane—launched its AmnioFix Injectable product, its newest tissue offering.

AmnioFix Injectable is an allograft composed of micronized amniotic tissue, processed to optimize surgical performance and ease of use, according to a release issued by the firm. The company’s proprietary Purion process retains the amniotic growth factors and cytokines inherent in and unique to placental tissue. The result is an injectable tissue that, the company claims, offers surgeons a “clear advantage” due to its natural ability to reduce inflammation at the injection site and enhance soft tissue healing. Another advantage is the product’s five-year, room temperature shelf life.

The Purion process was developed by the company’s Surgical Biologics subsidiary, which has supplied more than 60,000 implants to date to distributors and OEMs for application in the ophthalmic, orthopedics, spine, wound care and dental sectors of healthcare, according to the company.

In addition to AmnioFix Injectable, MiMedx also highlighted its AmnioFix Wrap for nerve and tendon applications. AmnioFix Nerve Wrap, an allograft from amniotic tissue that is used for various nerve repair surgical procedures, and was launched last year. It is a composite allograft structure of amniotic membrane layers, designed for use as an in-vivo wrap in peripheral nerve and tendon trauma. The Wrap product provides a protective barrier and contributes to the three phases of the natural healing process, according to the company: the inflammatory phase, proliferation phase and remodeling phase. In-vivo studies have confirmed that the properties of amniotic membrane help to reduce scar tissue formation and scar attachments to injured/repaired nerves and tendons, officials noted during AAOS.

“We are expanding our presence at the AAOS in order to serve the growing interests among physicians for minimally manipulated tissue offerings that address the clinical efficacy and cost effectiveness needs of these critical areas of healthcare,” said Pete Petit, chairman and CEO, said.

Bill Taylor, president and COO, of the Kennesaw (just outside of Atlanta), Ga.-based firm said AAOS provided a perfect opportunity to showcase the company’s growing technology portfolio.

“We are very pleased to be able to take advantage of this outstanding forum for physicians and scientists to gather and witness the remarkable potential of our AmnioFix technology for numerous medical applications in the areas of soft tissue trauma, nerve and tendon repair, spinal applications and sports medicine,” Taylor said.

MiMedx’s biomaterial platform technologies include the device technologies HydroFix and CollaFix, and tissue technologies, AmnioFix and EpiFix.